Merck applied for emergency use authorisation for COVID-19 pill in US

 

The treatment, molnupiravir, cuts the rate of hospitalisation and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released.

Share on facebook
Share on twitter
Share on whatsapp
Share on email

Subscribe and get top news delivered to your Inbox everyday for FREE